Overactive Bladder in the Elderly


Course Information for Audit
This educational site can still be audited free of charge. As an added feature, it is now available for accreditation for pharmacists.
Course Information for Accreditation
The following information pertains to accreditation only. Before you proceed to registration, please review the learning objectives and content of the entire site. Target Audience Geriatric health-care practitioners Accreditation At this time we are offering CE for pharmacists only. The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
CE Release Date: September 30, 2007 CE Expiration Date: September 30, 2010
This program (INDIVIDUAL PROGRAM NUMBER ACPE #203-999-07-138-H01) qualifies for 0.20 CEUs (2.0 contact hours) of continuing pharmacy education. CEUs will be awarded provided that the participant reviews this site and scores 70% or better on the post test that follows. To receive a statement of credit, please complete the examination and evaluation that follows this program. A statement will be awarded and mailed to you within 4-6 weeks.
Content Development Author: Manju T. Beier, Pharm..D., FASCP Partner, Geriatric Consultant Resources, LLC Clinical Associate Professor, College of Pharmacy University of Michigan, Ann Arbor, Michigan, USA Disease-specific Site on Overactive Bladder in the Elderly for Healthcare Professionals This program will qualify for 0.20 CEUs (2.0 contact hours) of continuing pharmacy education. CEUs will be awarded provided that the participant reviews this site and scores 70% or better on the post-test that follows. Learning Objectives At the end of this session, the online user should be able to: Discuss the definition, prevalence, and economic burden of urinary incontinence, and overactive bladder in the older adult. Distinguish the different subtypes of urinary incontinence and overactive bladder according to their pathophysiology, and clinical features in the older adult. Outline the consequences of untreated overactive bladder in the elderly. Enumerate medications and disease conditions implicated in causing urinary incontinence and overactive bladder in the older adult. Briefly describe the preferred pharmacotherapy for each type of urinary incontinence including the side effects of the therapeutic drug class. Identify the side effects, drug-drug interactions, and monitoring parameters for antimuscarinics used for management of overactive bladder in the older adult. Discuss the pivotal clinical trials comparing and contrasting the antimuscarinic medications for overactive bladder. Briefly describe the selection criteria for choosing the most appropriate medication for overactive bladder given the multiple medications and diseases in any given older adult. Describe the evidence-based practice guidelines on urinary incontinence and overactive bladder from professional organizations. Enumerate some novel pharmacologic therapies being investigated for the management of urinary incontinence in the elderly.

Privacy Policy / Disclaimer [MAIN] [ SENIOR CARE RESOURCES] [CONTINUING EDUCATION] [WHAT'S NEW/CONTACT GCR] [PROFESSIONAL LINKS] [DISEASE SPECIFIC SITES]